Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly currently in Phase 3 clinical trials for obesity and metabolic disorders. It is a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon receptors simultaneously — making it the most mechanistically comprehensive compound in its class. For research sourcing, see the Retatrutide research peptide page. This guide covers the mechanism, the Phase 2 trial data, how it compares to other GLP compounds, and handling requirements for research.
The Triple Agonist Mechanism
What makes Retatrutide distinct from predecessors like semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) is the addition of glucagon receptor agonism. Each receptor pathway contributes differently to metabolic outcomes:
- GLP-1 (Glucagon-like peptide-1): Reduces appetite, slows gastric emptying, stimulates glucose-dependent insulin secretion
- GIP (Glucose-dependent insulinotropic polypeptide): Enhances insulin secretion, plays a role in adipose tissue lipid metabolism
- Glucagon receptor: Increases energy expenditure, promotes hepatic fat mobilization and lipolysis — this is the key differentiator from tirzepatide
The glucagon component is responsible for Retatrutide’s pronounced effect on adipose tissue reduction. It also means Retatrutide introduces more complex metabolic signaling than dual agonists, which researchers need to account for in study design.
Phase 2 Trial Data Overview
The pivotal Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled adults with BMI ≥30 or BMI 27-30 with a weight-related comorbidity, running 24 weeks with a dose-escalation design. Key findings:
- Mean body weight reduction of 17.5% at the highest dose (12mg) vs 1.6% placebo at 24 weeks
- 24.2% weight reduction observed in the longest exposure cohort
- Fasting glucose reductions were dose-dependent
- Most common adverse events were gastrointestinal (nausea, vomiting, diarrhea) — consistent with GLP-1 class effects
- Half-life approximately 6 days, enabling weekly administration
Retatrutide vs Tirzepatide: Research Design Considerations
For researchers choosing between Retatrutide and Tirzepatide, the primary distinction is the glucagon component. Tirzepatide (dual GIP/GLP-1) is the cleaner model for studying GIP-GLP-1 interaction without glucagon confounding. Retatrutide is the correct choice when the research question specifically involves maximal adipose mobilization, hepatic lipid metabolism, or the differential contribution of glucagon receptor agonism to metabolic outcomes.
Both compounds are studied under the GLP-3RT designation in CoreVionRX’s catalog — see the GLP-3RT research quality and handling guide for COA documentation standards and preparation protocol specific to GLP compounds.
Metabolic Research Applications
Obesity and Body Composition Models
Retatrutide’s most studied application is high-fat diet-induced obesity in rodent models and the Phase 2/3 human trials. Body composition outcomes (lean vs fat mass) require DEXA or equivalent assessment at 8-16 week minimum endpoints to show statistically meaningful changes.
Glycemic Control and Insulin Sensitivity
Fasting glucose, postprandial glucose, and HOMA-IR are the primary metabolic markers in Retatrutide research. Early changes (2-4 weeks in animal models) are observable in insulin sensitivity; full metabolic adaptation requires 8-12 weeks for meaningful data.
Hepatic Fat and MASLD Models
Retatrutide is currently in Phase 3 trials for metabolic-associated steatotic liver disease (MASLD). The glucagon agonism component contributes directly to hepatic fat mobilization, making it a compound of interest in NASH/MASLD preclinical research.
Study Window and Protocol Notes
Meaningful metabolic outcomes require 8-16 week study windows minimum. Retatrutide’s 6-day half-life means weekly administration protocols are appropriate. Due to GI side effects (common with GLP-1 class), dose escalation protocols are standard — typically 2-4 weeks at each dose level before escalating. See Peptide Cycles 101 for general cycle structure considerations applicable to GLP compound research.
Handling and Storage
Retatrutide ships as lyophilized powder. Store at -20°C protected from light. Once reconstituted with bacteriostatic water, store at 2-8°C and use within 28 days. GLP class peptides are particularly sensitive to improper reconstitution technique — use the peptide reconstitution calculator to determine exact volumes, and draw water slowly along the inside wall of the vial rather than directly into the powder. Do not shake; swirl gently.
Key Published References
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
- Coskun T, et al. (2022). LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Molecular Metabolism. PMID: 35500778
Related Research Resources
- Retatrutide Research Peptide — Product Page
- Tirzepatide Research Peptide — Compare Dual vs Triple Agonist
- GLP-3RT Research Quality and Handling Guide
- Peptide Reconstitution Calculator
- Peptide Cycles 101: Research Protocols
All information is for laboratory research purposes only. CoreVionRX compounds are not intended for human use, diagnosis, or treatment.
